Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3219197 | 0.89 | CA12 (0.44) | MAPK1TSHRCA12CA14ALDH1A1 | |
| SCHEMBL3218897 | 0.82 | GAA (0.44) | MAPK1TSHRCA12CA14ALDH1A1 | |
| SCHEMBL3218741 | 0.81 | ALDH1A1 (0.45) | TSHRALDH1A1MAPTCYP3A4HPGD | |
| SCHEMBL16267663 | 0.80 | MAPK1 (0.59) | MAPK1CA12CA14ALDH1A1CA7 | |
| SCHEMBL5127346 | 0.79 | CA2 (0.64) | TSHRCA12CA14ALDH1A1CA2 | |
| SCHEMBL22404312 | 0.78 | CA12 (0.60) | MAPK1TSHRCA12CA14ALDH1A1 | |
| SCHEMBL3221256 | 0.77 | CA2 (0.60) | CA12CA14CA2CA7CA9 | |
| SCHEMBL3208060 | 0.76 | CA2 (0.38) | CA12CA14ALDH1A1CA2CA7 | |
| SCHEMBL7085537 | 0.76 | CA2 (0.63) | CA12CA14CA2CA7CA9 | |
| SCHEMBL3208052 | 0.75 | CA2 (0.38) | CA12CA14CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041892-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2010-02-18 | — | — | US | disclosed |
| US-20090270631-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2009-10-29 | — | — | US | disclosed |
| EP-1912645-A2 | THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-10 | — | — | US | disclosed |
| WO-2007018314-A2 | THERAPEUTIC AGENT FOR DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270631-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | MAPK1 851/4885TSHR 1577/4885CA12 3251/4885 |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | FABP4, SLC5A1, SLC5A2 | MAPK1 932/4885TSHR 808/4885CA12 3135/4885 |
| US-20100041892-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | MAPK1 851/4885TSHR 1577/4885CA12 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.